Medicine and Health Sciences Commons^™

Combination Of Vandetanib, Radiotherapy, And Irinotecan In The Lovo Human Colorectal Cancer Xenograft Model., Phyllis Wachsberger, Randy Burd, Anderson Ryan, Constantine Daskalakis, Adam P. Dicker

Department of Radiation Oncology Faculty Papers

PURPOSE: The tumor growth kinetics of the human LoVo colorectal xenograft model was assessed in response to vandetanib, an orally available receptor tyrosine kinase inhibitor, radiotherapy (RT), or irinotecan (CPT-11), as single therapies and in combination. METHODS AND MATERIALS: LoVo cells were injected subcutaneously into the right hind limb (5 x 10(6) cells in 100 microL phosphate-buffered saline) of athymic NCR NUM mice and tumors were grown to a volume of 200-300 mm(3) before treatment. Vandetanib was administered at 50 mg/kg daily orally for 14 days starting on Day 1. RT was given as three fractions (3 x 3 Gy) …

Oncolog Volume 54, Number 07/08, July/August 2009, John Lebas, Sunni Hosemann, Bryan Tutt

OncoLog MD Anderson's Report to Physicians (All issues)

• Frontiers in Radiosurgery
• Advanced Ovarian Cancer
• House Call: Colorectal Cancer: Life-Saving Options for Early Detection
• Reduced Wait Times Mean Faster Access for New Patients

Oncolog Volume 54, Number 05, May 2009, John Lebas

OncoLog MD Anderson's Report to Physicians (All issues)

• Targeting Inflammation in Cancer Prevention
• Treating Radiation Necrosis of the Brain
• Preclinical Studies Reveal Effectiveness of Therapies for Pediatric Cancers
• House Call: Protect and Check Your Skin